|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.86 USD | +8.60% |
|
+11.25% | +79.17% |
| 07-09 | Forte Biosciences, Inc. - Special Call | |
| 07-09 | Top Midday Gainers | MT |
Company Valuation: Forte Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,194 | - | - |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 145.53% | - | - |
| Enterprise Value (EV) | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,194 | 1,194 | 1,194 |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 145.53% | 0% | 0% |
| P/E | -1.38x | -1.25x | - | -1.87x | -5.79x | -11.9x | -11.5x | -11.2x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | - | - | 0.1x | 0.9x | -3.23x | -3.93x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | -0x | -0x | -12.3x | -9.15x | -7.59x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -38.75 | -20 | - | -12.17 | -4.71 | -4.106 | -4.252 | -4.373 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -36.6 | -70.66 | -97.38 | -130.5 | -157.2 |
| Net income 1 | -21.71 | -13.88 | - | -35.48 | -69.38 | -95.54 | -130.4 | -155.7 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 53.50 | 25.00 | 20.54 | 22.71 | 27.27 | 48.86 | 48.86 | 48.86 |
| Nbr of stocks (in thousands) | 590 | 840 | 1,453 | 6,393 | 17,831 | 24,436 | - | - |
| Announcement Date | 31/03/22 | 31/03/23 | 18/03/24 | 28/03/25 | 31/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.9x | - | - | - | 1.19B | |
| 19.5x | 6.01x | 13.15x | 1.63% | 52.1B | |
| 32.22x | 8.13x | 25.24x | 0.05% | 53.83B | |
| -42.48x | 13.5x | -39.59x | -.--% | 23.48B | |
| -18.22x | 4.32x | -7.57x | -.--% | 23.13B | |
| 24.24x | 4.75x | 12.54x | -.--% | 19.36B | |
| 24.39x | 4.78x | 15.56x | -.--% | 17.56B | |
| 45.88x | 18.59x | 47.88x | 0.08% | 15.2B | |
| -505.73x | 35.47x | -1462.84x | -.--% | 14.83B | |
| 17.57x | 5.11x | 11.88x | -.--% | 14.06B | |
| Average | -41.45x | 11.19x | -153.75x | 0.2% | 23.47B | |
| Weighted average by Cap. | -18.49x | 9.52x | -82.82x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBRX Stock
- Valuation Forte Biosciences, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
